441 related articles for article (PubMed ID: 36184326)
21. Amyloid-Related Imaging Abnormalities With Anti-amyloid Antibodies for the Treatment of Dementia Due to Alzheimer's Disease.
Withington CG; Turner RS
Front Neurol; 2022; 13():862369. PubMed ID: 35401412
[TBL] [Abstract][Full Text] [Related]
22. Comparative Efficacy, Tolerability, and Acceptability of Donanemab, Lecanemab, Aducanumab, Melatonin, and Aerobic Exercise for a Short Time on Cognitive Function in Mild Cognitive Impairment and Mild Alzheimer's Disease: A Systematic Review and Network Meta-Analysis.
Terao I; Kodama W
J Alzheimers Dis; 2024; 98(3):825-835. PubMed ID: 38461503
[TBL] [Abstract][Full Text] [Related]
23. Immunotherapies Targeting Amyloid and Tau Protein in Alzheimer's Disease: Should We Move Away from Diseases and Focus on Biological Targets? A Systematic Review and Expert Opinion.
Esquer A; Blanc F; Collongues N
Neurol Ther; 2023 Dec; 12(6):1883-1907. PubMed ID: 37812325
[TBL] [Abstract][Full Text] [Related]
24. Amyloid-Related Imaging Abnormalities (ARIA) in Immunotherapy Trials for Alzheimer's Disease: Need for Prognostic Biomarkers?
Piazza F; Winblad B
J Alzheimers Dis; 2016 Mar; 52(2):417-20. PubMed ID: 27031492
[TBL] [Abstract][Full Text] [Related]
25. Effects of three kinds of anti-amyloid-β drugs on clinical, biomarker, neuroimaging outcomes and safety indexes: A systematic review and meta-analysis of phase II/III clinical trials in Alzheimer's disease.
Lyu D; Lyu X; Huang L; Fang B
Ageing Res Rev; 2023 Jul; 88():101959. PubMed ID: 37217078
[TBL] [Abstract][Full Text] [Related]
26. Results from the long-term extension of PRIME: A randomized Phase 1b trial of aducanumab.
Chen T; O'Gorman J; Castrillo-Viguera C; Rajagovindan R; Curiale GG; Tian Y; Patel D; von Rosenstiel P; von Hehn C; Salloway S; Hock C; Nitsch RM; Haeberlein SB; Sandrock A; Singhal P
Alzheimers Dement; 2024 May; 20(5):3406-3415. PubMed ID: 38567735
[TBL] [Abstract][Full Text] [Related]
27. Alzheimer's Amyloid Hypothesis and Antibody Therapy: Melting Glaciers?
Høilund-Carlsen PF; Alavi A; Castellani RJ; Neve RL; Perry G; Revheim ME; Barrio JR
Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612701
[TBL] [Abstract][Full Text] [Related]
28. Role of Aducanumab in the Treatment of Alzheimer's Disease: Challenges and Opportunities.
Vaz M; Silva V; Monteiro C; Silvestre S
Clin Interv Aging; 2022; 17():797-810. PubMed ID: 35611326
[TBL] [Abstract][Full Text] [Related]
29. Donanemab: Not two without a third.
Kurkinen M
Adv Clin Exp Med; 2023 Oct; 32(10):1085-1087. PubMed ID: 37831471
[TBL] [Abstract][Full Text] [Related]
30. Detection and Management of Amyloid-Related Imaging Abnormalities in Patients with Alzheimer's Disease Treated with Anti-Amyloid Beta Therapy.
Barakos J; Purcell D; Suhy J; Chalkias S; Burkett P; Marsica Grassi C; Castrillo-Viguera C; Rubino I; Vijverberg E
J Prev Alzheimers Dis; 2022; 9(2):211-220. PubMed ID: 35542992
[TBL] [Abstract][Full Text] [Related]
31. Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer's disease: A systematic review.
Chowdhury S; Chowdhury NS
Int J Immunopathol Pharmacol; 2023; 37():3946320231209839. PubMed ID: 37902139
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of anti-amyloid-ß monoclonal antibody therapy in early Alzheimer's disease: a systematic review and meta-analysis.
Dantas JM; Mutarelli A; Navalha DDP; Dagostin CS; Romeiro PHCL; Felix N; Nogueira A; Batista S; Teixeira L; Caramelli P
Neurol Sci; 2024 Jun; 45(6):2461-2469. PubMed ID: 37978096
[TBL] [Abstract][Full Text] [Related]
33. The Future of AD Clinical Trials with the Advent of Anti-Amyloid Therapies: An CTAD Task Force Report.
Delrieu J; Bateman RJ; Touchon J; Sabbagh M; Cummings J
J Prev Alzheimers Dis; 2022; 9(3):393-399. PubMed ID: 35841240
[TBL] [Abstract][Full Text] [Related]
34. Identifying Genetic Risk for Amyloid-Related Imaging Abnormalities.
Hardy J; Schott JM
Neurology; 2024 Feb; 102(3):e208096. PubMed ID: 38165303
[TBL] [Abstract][Full Text] [Related]
35. Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease.
Söderberg L; Johannesson M; Nygren P; Laudon H; Eriksson F; Osswald G; Möller C; Lannfelt L
Neurotherapeutics; 2023 Jan; 20(1):195-206. PubMed ID: 36253511
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
[TBL] [Abstract][Full Text] [Related]
37. Updated safety results from phase 3 lecanemab study in early Alzheimer's disease.
Honig LS; Sabbagh MN; van Dyck CH; Sperling RA; Hersch S; Matta A; Giorgi L; Gee M; Kanekiyo M; Li D; Purcell D; Dhadda S; Irizarry M; Kramer L
Alzheimers Res Ther; 2024 May; 16(1):105. PubMed ID: 38730496
[TBL] [Abstract][Full Text] [Related]
38. Bayesian meta-analysis of phase 3 results of aducanumab, lecanemab, donanemab, and high-dose gantenerumab in prodromal and mild Alzheimer's disease.
Teipel SJ; Temp AGM; Lutz MW
Alzheimers Dement (N Y); 2024; 10(1):e12454. PubMed ID: 38389855
[TBL] [Abstract][Full Text] [Related]
39. Disease Modeling and Model-Based Meta-Analyses to Define a New Direction for a Phase III Program of Gantenerumab in Alzheimer's Disease.
Retout S; Gieschke R; Serafin D; Weber C; Frey N; Hofmann C
Clin Pharmacol Ther; 2022 Apr; 111(4):857-866. PubMed ID: 35100444
[TBL] [Abstract][Full Text] [Related]
40. Vascular Considerations for Amyloid Immunotherapy.
Foley KE; Wilcock DM
Curr Neurol Neurosci Rep; 2022 Nov; 22(11):709-719. PubMed ID: 36269539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
